Defence Therapeutics Inc.DTC.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · defencetherapeutics.com
Defence Therapeutics Inc. is a Montreal-based preclinical biotechnology company developing precision oncology therapeutics with its proprietary Accum® intracellular drug-delivery platform, aimed at improving the potency of antibody-drug conjugates, radiopharmaceuticals (alpha- and beta-emitter radio-immunoconjugates) and other complex biologics at lower doses.
Key ratios
ROA
-40.1%TTM
2025
-187.3%2024
-397.3%2023
-190.9%
ROE
-232.8%TTM
2023
-1147.6%
Recent news
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Defence Therapeutics Provides Updates on Sharing Agreement
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Track DTC.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer